Você no controle da sua respiração

Fale Conosco, Termos e Condições e Política de Privacidade

Legal Notice

Last Modified (April 2019)

This website (“Website”) is provided to you under these "Terms of Use" and any amendments or supplements to them (collectively referred to as this "Agreement") that may be posted by Genzyme Corporation or one of its affiliated companies (collectively, “Site Owner,” "we", "us") from time to time. Your use of this Website, or any other services or content provided through the Website shall be deemed to constitute your consent to be legally bound by the terms and conditions of the Agreement, which shall be enforceable in the same way as if you had signed the Agreement. If you are not willing to accept the terms and conditions in the Agreement, we ask that you not access or use the Website.

WEBSITE INTENDED AUDIENCE

This Website is available to adults globally.

INFORMATION DISCLAIMER

This website, including any advice and recommendations on the Website, is intended solely as a general educational aid to raise awareness about severe asthma.

The information on this Website is not intended as medical or healthcare advice, or to be used for medical diagnosis or treatment, for any individual problem. It is also not intended as a substitute for professional advice and services from a qualified healthcare provider familiar with your unique facts. Always seek the advice of your doctor or other qualified healthcare provider regarding any medical condition and before starting any new treatment. Your use of the site is subject to the additional disclaimers and caveats that may appear throughout the Website.

We assume no responsibility for any consequence relating directly or indirectly to any action or inaction you take based on the information, services, or other material on the Website. While we strive to keep the information on the Website accurate, complete, and up-to-date, we do not give any assurances, and will not be responsible for, any damage or loss related to the accuracy, completeness, or timeliness of the information on the Website.

OWNERSHIP

You understand that the Website is available for your personal, non-commercial use only. You agree that the Website is the property of the Site Owner; including all intellectual property rights in it and that you have no right to use them other than as set out in these Terms of Use. We are not responsible for any harm or loss that you suffer in relation to any use you make of the Website for any business purposes or other purposes not authorized under these Terms of Use. We reserve the right to refuse or terminate access to the Website at our discretion. The Website are provided free of charge and on that basis we have no obligation to provide any maintenance or support services in relation to them and we are not responsible for any loss or damage you may suffer as a result of any failure to maintain or update the Website.

You may not copy, change or reuse the Website, any updates to them or any part of them including the software incorporated in them.

You may use this Website only for lawful purposes and in accordance with these Terms of Use. You are granted a nonexclusive, nontransferable, revocable, limited license to view, print and distribute content retrieved from the Website for your personal, noncommercial purposes, provided that you do not remove or obscure the copyright notice or other notices displayed on the content. You may not copy, reprint, modify, display, perform, translate, distribute, adapt, broadcast, communicate to the public by telecommunication, circulate, or sell the content retrieved from the Website in any way, for any commercial use or provide it to any commercial source, including other websites, without the prior written permission of Site Owner.

In addition, you agree not to:

use this Website in any manner that could disable, overburden, damage, or impair this Website, or interfere with any other use of this Website, including, any user's ability to engage in real-time activities through this Website;
use any robot, spider or other automatic device, process or means to access this Website for any purpose, including to scrape, data mine, monitor or copy any of the material on this Website;
use any manual process to monitor or copy any of the material on this Website, or to engage in any other unauthorized purpose without the express prior written consent of Site Owner;
otherwise use any device, software or routine that interferes with the proper working of this Website; or
otherwise attempt to interfere with the proper working of this Website.

We reserve all rights not expressly granted to you.

PRIVACY AND CONSENT TO USE DATA

The information that we obtain through your use of the Website is subject to our Privacy Policy (the privacy policy can be accessed by clicking the appropriate tab found here). Our Privacy Policy addresses our collection and use of the data you provide to us, including your rights relative to that information.

To the extent personal data is obtained through the website, Genzyme Corporation is data controller for the processing of that personal data.

Genzyme Corporation:
50 Binney Street,
Cambridge,
Massachusetts 02142
Tel.: +1 (617) 252-7500

SITE HOSTING
Microsoft Nederland B.V. Evert van de Beekstraat 354
1118 CZ Schiphol (Amsterdam) The Netherlands

ELECTRONIC COMMUNICATIONS

The information communicated on the Website constitutes an electronic communication. When you communicate with us through the Website or via other forms of electronic media, such as e-mail, you are communicating with us electronically. You agree that we may communicate electronically, subject to local privacy laws, and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.

DISCLAIMER OF WARRANTIES WITH RESPECT TO USE OF WEBSITE

The Website is provided on an “as is” and “as available” basis. Except as specifically provided herein, to the fullest extent permissible pursuant to applicable law, Site Owner expressly disclaims all warranties of any kind, whether express, legal or implied, including, without limitation, any warranties of merchantability, fitness for a particular purpose and non-infringement.

Site owner does not make any warranty that the Website will meet your requirements, or that access to the Website will be uninterrupted, timely, secure, or error-free, or that defects, if any, will be corrected. Site owner makes no warranties as to the results that may be obtained from the use of the Website or as to the accuracy, quality, or reliability of any information obtained through the website.

You understand and agree that any material and/or data downloaded or otherwise obtained through the use of the Website is used at your own risk and that you will be solely responsible for any damage to your computer system or loss of data that results from the download of such material and/or data.

No advice or information, whether oral or written, obtained by you from Site Owner or through the Website shall create any warranty not expressly made herein.

LIMITATIONS OF LIABILITY

You expressly understand and agree that under no circumstances will Site Owner, its affiliates and any of their respective directors, officers, employees, agents, mandataries or other representatives be liable for direct, indirect, special, incidental, consequential, punitive or aggravated damages, including, without limitation, any loss of use, loss of income, saving or profits, loss of data, loss of goodwill, cost of procurement of substitute services, or any other indirect, special, incidental, or consequential damages, howsoever caused, and on any theory of liability, whether for breach of contract, tort (including negligence and strict liability), or otherwise resulting from (1) the use of, or the inability to use, the Website; (2) the cost of procurement of substitute services, items, or websites; (3) unauthorized access to or alteration of your transmissions or data (including personal information); (4) the statements or conduct of any third party on the Website; or (5) any other matter relating to the Website. These limitations will apply whether or not Site Owner has been advised of the possibility of such damages and notwithstanding any failure of essential purpose of any limited remedy. This exclusion of liability shall apply to the fullest extent permitted by applicable laws.

TRADEMARK NOTICES

The trademarks and brand names displayed on this Website are the property of Site Owner, its affiliates or third party owners. You may not use or display any trademarks or service marks owned by Site Owner without our prior written consent. You may not use or display any other trademarks or service marks displayed on this Website without the permission of their owners.

MODIFICATION OR SUSPENSION OF THE WEBSITE

We will make reasonable efforts to make the Website available but we may from time to time need to interrupt, restrict, modify or discontinue, temporarily or permanently the Website or parts of it without notice. We will not be responsible for any harm or loss you may suffer as a result of such actions.

TERMINATION

We may at any time terminate your use of or access to the Website if we have a good reason to do so which includes any breach by you of these Terms of Use and any other relevant guidelines. We will not be responsible for any loss or harm you may suffer as a result of termination of your use of the Website in these circumstances. In the event of any termination you must stop using the Website and you agree that the provisions of the Agreement regarding Ownership, Trademark Notices, Indemnification, Disclaimer or Warranties, Limitations of Liability, and Applicable Law shall survive any such termination.

LINKS TO THIRD PARTY SITES

This Website may contain links or references to third party websites. These links are provided for your convenience only. No endorsement of any third party products, services or information is expressed or implied by any information, material or content of any third party contained in, referred to, included on, or linked from or to this Website. Any information, data, opinions, recommendations, products or services provided by such third parties through links to other websites or otherwise made available through their websites are solely those of such third parties and not of Site Owner. Your use of such third party websites is subject to the terms of use and the privacy policies of such websites.

INDEMNIFICATION

You agree to indemnify and hold harmless Site Owner and its affiliates and their respective directors, officers, employees, agents, or other representatives from and against all claims, liability, damages and expenses, including without limitation all legal fees and costs arising from or relating to (a) your breach of these Terms of Use; (b) your use of this Website including without limitation transmission or placement of information or material by you on this Website; and (c) any claim or allegation that any of your User Content infringes the intellectual property or other proprietary rights, or privacy rights, of any third party.

MODIFICATIONS TO THESE TERMS

We may make changes to the Terms of Use from time to time in our sole discretion, by updating these Terms of Use on this Website, and specifying the effective date of the new version of the Terms of Use. The “Last Modified” date at the top of these Terms of Use will indicate when the latest changes were made. Your continued use of the Website following the posting of a new version of the Terms of Use constitutes your acceptance of any such changes. Accordingly, whenever you visit this Website, you should check to see if a new version of the Agreement has been posted.

CONTACT INFORMATION

If you have any questions or concerns with respect to these Terms of Use or the Website you may contact us as identified in the Contact Us section of this Website.

SEVERABILITY OF AGREEMENT

Should any part or provision of these Terms of Use be held unlawful, void, invalid, or unenforceable that portion shall be deemed severable from these Terms of Use and shall not affect the validity and enforceability of any remaining provisions.

SURVIVAL

All Sections shall survive the termination of the right to use the Website.

APPLICABLE LAW AND JURISDICTION

The information on the Website is intended for audiences globally. The Agreement and the resolution of any dispute related to the Agreement, the Website, or items you purchase through the Website, and any non-contractual obligations arising out of or in connection with these Terms of Use, shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts in the United States of America and you agree to submit to the personal and exclusive jurisdiction of such courts.

Referências

Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.
Heffler, Enrico, et al. “The Severe Asthma Network in Italy: Findings and Perspectives.” The Journal of Allergy and Clinical Immunology: In Practice 7.5 (2019): 1462-1468.
Shaw DE, et al Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46:1308–1321.
Maio S, et al RItA: The Italian severe/uncontrolled asthma registry. Allergy. 2018;73:683–695.
Dharmage, Shyamali C., Jennifer Perret, and Adnan Custovic. Epidemiology of asthma in children and adults. Frontiers in paediatrics. 7 (2019): 246.
Network GA. The Global Asthma Report, Auckland, New Zealand. (2018).
Larsson K, Ställberg B, Lisspers K, Telg G, Johansson G, Thuresson M, Janson C. Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). Respiratory research. 2018 Dec 1;19(1):12.
von Bülow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. The Journal of Allergy and Clinical Immunology: In Practice. 2014 Nov 1;2(6):759-67.
Tay, T. R., Radhakrishna, N., Hore‐Lacy, F., Smith, C., Hoy, R., Dabscheck, E., & Hew, M. (2016). Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology, 21(8), 1384-1390.
Fletcher M, Hiles D. Continuing discrepancy between patient perception of asthma control and real-world symptoms: a quantitative online survey of 1,083 adults with asthma form the UK. Prim Care Resp J. 2013;22(4):431-438.
Murphy KR, Meltzer EO, Blaiss MS, Nathan RA, Stoloff SW, Doherty DE. Asthma management and control in the United States: results of the 2009 Asthma Insight and Management survey. In Allergy & Asthma Proceedings. 2012 Jan 1 (Vol. 33, No. 1).
Vennik J, Eyles C, Thomas M, Hopkins C, Little P, Blackshaw H, Schilder A, Boardman J, Philpott CM. Management strategies for chronic rhinosinusitis: a qualitative study of GP and ENT specialist views of current practice in the UK. BMJ open. 2018 Dec 1;8(12).
Andrews KL et al. Stigma: Still an Important Issue for Adults With Asthma. Journal of Asthma and Allergy Educators. Vol 4, Issue 4, 2013.
Reddel HK, et al. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open. 2017;7:e016688. Available at: https://bmjopen.bmj.com/content/7/9/e016688.full?ijkey=JWTMTG1oSaXXktC&keytype=ref.
GINA 2020 Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2020. Available at: https://ginasthma.org/gina-reports/. Last accessed April 2020.
Peters MC, Mekonnen ZK, Yuan S, et al. Measure of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388-394.
Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017: 47(2): 161-175.
Fahy JV. Type 2 inflammation in asthma — present in most, absent in many. Nat Rev lmmunol. 2015;15(1):57-65.
Global Initiative for Asthma (GINA). Pocket Guide for Asthma Management and Prevention. 2020. Available at: https://ginasthma.org/wp-content/uploads/2020/04/Main-pocket-guide_2020_04_03-final-wms.pdf. Last Accessed April 2020.
Behmanesh F, et al. Evaluation of anxiety and depression in mothers of children with asthma. Electron Physician. 2017:9(12);6058-6062.
Asthma and Allergy Foundation of America. My Life with Asthma Report. Available at http://www.aafa.org/my-life-with-asthma-report/. Last accessed October 2018.
Asthma and Allergy Foundation of America. My Life with Asthma Survey Overview. Available at: http://www.aafa.org/media/1684/my-life-with-asthma-in-2017-survey-findings-report.pdf. Last accessed October 2018.
Rand C, et al. Mediators of asthma outcomes. J Allergy Clin Immunol. 2012:129(3);136-141.
The European Academy of Allergy and Clinical Immunology (EAACI). Advocacy Manifesto: Tackling the Allergy Crisis in Europe - Concerted Policy Action Needed. Available at: http://www.eaaci.org/documents/EAACI_Advocacy_Manifesto.pdf. Last accessed October 2018.
European Respiratory Society. European Lung White Book, Chapter 2: The economic burden of lung disease. Available at: http://www.erswhitebook.org/files/public/Chapters/02_economics.pdf. Last accessed October 2018.
Daugherty J, et al. The impact of long-term systemic glucocorticoid use in severe asthma: A UK retrospective cohort analysis. J Asthma. 2017 Sep;19:1-8.
Nunes C, Pereira AM, Morais-Ameida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.
Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. New England Journal of Medicine. 2017 Sep 7;377(10):965-76.
Chipps et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2012 Aug;130(2):332-42.
Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
Dunican EM, Fahy JV. The Role of type 2 inflammation in the pathogenesis of asthma exacerbations. Ann Am Thorac Soc. 2015;12 Suppl 2:S144–S149.
Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347-58.
Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2015;308(2):L130-40.
Matsusaka M, K Fukunaga, H Kabata, et al. Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract. 2018;6(1):274-276.e2.
Fajt, M. L., & Wenzel, S. E. (2015). Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. Journal of Allergy and Clinical Immunology, 135(2), 299-310.
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464.
Khan A, Vandeplas G, Huynh TM, Joish VN, Mannent L, Tomassen P, Van Zele T, Cardell LO, Arebro J, Olze H, Foerster-Ruhrmann U. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42.
Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, ten Brinke A, Bel EH. Severe adult-onset asthma: a distinct phenotype. Journal of allergy and clinical immunology. 2013 Aug 1;132(2):336-41.
Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, Mahdavinia M, Grammer LC, Hulse KE, Kern RC, Avila P. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. The Journal of Allergy and Clinical Immunology: In Practice. 2017 Jul 1;5(4):1061-70.
Gudziol V, Michel M, Sonnefeld C, Koschel D, Hummel T. Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. European Archives of Oto-Rhino-Laryngology. 2017 Mar 1;274(3):1487-93.
Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45-53.
Partridge, M. R. Delivering optimal care to the person with asthma: what are the key components and what do we mean by patient education? Eur Respir J. 1995: 8: 298-305.
Asthma Society of Canada. Severe Asthma - The Canadian Patient Journey: A study of the personal, social, medical and economic burden of Severe Asthma in Canada. Available at: https://www.asthma.ca/wp-content/uploads/2017/06/SAstudy.pdf Last accessed: December 2018. 1-8.

Referências

1. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.
2. Heffler, Enrico, et al. “The Severe Asthma Network in Italy: Findings and Perspectives.” The Journal of Allergy and Clinical Immunology: In Practice 7.5 (2019): 1462-1468.
3. Shaw DE, et al Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46:1308–1321.
4. Maio S, et al RItA: The Italian severe/uncontrolled asthma registry. Allergy. 2018;73:683–695.
5. Dharmage, Shyamali C., Jennifer Perret, and Adnan Custovic. Epidemiology of asthma in children and adults. Frontiers in paediatrics. 7 (2019): 246.
6. Network GA. The Global Asthma Report, Auckland, New Zealand. (2018).
7. Larsson K, Ställberg B, Lisspers K, Telg G, Johansson G, Thuresson M, Janson C. Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). Respiratory research. 2018 Dec 1;19(1):12.
8. von Bülow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. The Journal of Allergy and Clinical Immunology: In Practice. 2014 Nov 1;2(6):759-67.
9. Tay, T. R., Radhakrishna, N., Hore‐Lacy, F., Smith, C., Hoy, R., Dabscheck, E., & Hew, M. (2016). Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology, 21(8), 1384-1390.
10. Fletcher M, Hiles D. Continuing discrepancy between patient perception of asthma control and real-world symptoms: a quantitative online survey of 1,083 adults with asthma form the UK. Prim Care Resp J. 2013;22(4):431-438.
11. Murphy KR, Meltzer EO, Blaiss MS, Nathan RA, Stoloff SW, Doherty DE. Asthma management and control in the United States: results of the 2009 Asthma Insight and Management survey. In Allergy & Asthma Proceedings. 2012 Jan 1 (Vol. 33, No. 1).
12. Vennik J, Eyles C, Thomas M, Hopkins C, Little P, Blackshaw H, Schilder A, Boardman J, Philpott CM. Management strategies for chronic rhinosinusitis: a qualitative study of GP and ENT specialist views of current practice in the UK. BMJ open. 2018 Dec 1;8(12).
13. Andrews KL et al. Stigma: Still an Important Issue for Adults With Asthma. Journal of Asthma and Allergy Educators. Vol 4, Issue 4, 2013.
14. Reddel HK, et al. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open. 2017;7:e016688. Available at: https://bmjopen.bmj.com/content/7/9/e016688.full?ijkey=JWTMTG1oSaXXktC&keytype=ref.
15. GINA 2020 Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2020. Available at: https://ginasthma.org/gina-reports/. Last accessed April 2020.
16. Peters MC, Mekonnen ZK, Yuan S, et al. Measure of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388-394.
17. Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017: 47(2): 161-175.
18. Fahy JV. Type 2 inflammation in asthma — present in most, absent in many. Nat Rev lmmunol. 2015;15(1):57-65.
19. Global Initiative for Asthma (GINA). Pocket Guide for Asthma Management and Prevention. 2020. Available at: https://ginasthma.org/wp-content/uploads/2020/04/Main-pocket-guide_2020_04_03-final-wms.pdf. Last Accessed April 2020.
20. Behmanesh F, et al. Evaluation of anxiety and depression in mothers of children with asthma. Electron Physician. 2017:9(12);6058-6062.
21. Asthma and Allergy Foundation of America. My Life with Asthma Report. Available at http://www.aafa.org/my-life-with-asthma-report/. Last accessed October 2018.
22. Asthma and Allergy Foundation of America. My Life with Asthma Survey Overview. Available at: http://www.aafa.org/media/1684/my-life-with-asthma-in-2017-survey-findings-report.pdf. Last accessed October 2018.
23. Rand C, et al. Mediators of asthma outcomes. J Allergy Clin Immunol. 2012:129(3);136-141.
24. The European Academy of Allergy and Clinical Immunology (EAACI). Advocacy Manifesto: Tackling the Allergy Crisis in Europe - Concerted Policy Action Needed. Available at: http://www.eaaci.org/documents/EAACI_Advocacy_Manifesto.pdf. Last accessed October 2018.
25. European Respiratory Society. European Lung White Book, Chapter 2: The economic burden of lung disease. Available at: http://www.erswhitebook.org/files/public/Chapters/02_economics.pdf. Last accessed October 2018.
26. Daugherty J, et al. The impact of long-term systemic glucocorticoid use in severe asthma: A UK retrospective cohort analysis. J Asthma. 2017 Sep;19:1-8.
27. Nunes C, Pereira AM, Morais-Ameida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.
28. Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. New England Journal of Medicine. 2017 Sep 7;377(10):965-76.
29. Chipps et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2012 Aug;130(2):332-42.
30. Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
31. Dunican EM, Fahy JV. The Role of type 2 inflammation in the pathogenesis of asthma exacerbations. Ann Am Thorac Soc. 2015;12 Suppl 2:S144–S149.
32. Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347-58.
33. Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2015;308(2):L130-40.
34. Matsusaka M, K Fukunaga, H Kabata, et al. Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract. 2018;6(1):274-276.e2.
35. Fajt, M. L., & Wenzel, S. E. (2015). Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. Journal of Allergy and Clinical Immunology, 135(2), 299-310.
36. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464.
37. Khan A, Vandeplas G, Huynh TM, Joish VN, Mannent L, Tomassen P, Van Zele T, Cardell LO, Arebro J, Olze H, Foerster-Ruhrmann U. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42.
38. Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, ten Brinke A, Bel EH. Severe adult-onset asthma: a distinct phenotype. Journal of allergy and clinical immunology. 2013 Aug 1;132(2):336-41.
39. Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, Mahdavinia M, Grammer LC, Hulse KE, Kern RC, Avila P. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. The Journal of Allergy and Clinical Immunology: In Practice. 2017 Jul 1;5(4):1061-70.
40. Gudziol V, Michel M, Sonnefeld C, Koschel D, Hummel T. Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. European Archives of Oto-Rhino-Laryngology. 2017 Mar 1;274(3):1487-93
41. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45-53.
42. Partridge, M. R. Delivering optimal care to the person with asthma: what are the key components and what do we mean by patient education? Eur Respir J. 1995: 8: 298-305.
43. Asthma Society of Canada. Severe Asthma - The Canadian Patient Journey: A study of the personal, social, medical and economic burden of Severe Asthma in Canada. Available at: https://www.asthma.ca/wp-content/uploads/2017/06/SAstudy.pdf Last accessed: December 2018. 1-8.

Privacy Policy

WHY THIS DOCUMENT?

As part of its day to day operation, SANOFI provides access to a variety of tools and resources which are destined to provide information to all the individuals with whom it has business interactions with (patients and their relatives, participants to clinical trials, healthcare professionals, users of products and services, workers, etc.) regarding its activities.

Such tools and resources may be provided in various formats, including, more specifically in electronic format and by means of online electronic communications, including the website available at www.sanofi.com and any other website made available by SANOFI and to which this policy applies (hereinafter together the “Website”). In order to be able to provide them, SANOFI may need to collect and process Personal Data (as defined below) of their users.

SANOFI is fully committed to the protection of Personal Data and intends to provide you with all relevant information regarding the way in which SANOFI processes your Personal Data on the Website.

You will therefore find below all relevant information regarding the processing of Personal Data conducted on this Website. Please note that the content of this Website Privacy Policy may change from time to time, for instance in case of evolution of our processes or as a result of applicable law. Should these changes be objectively substantial and affect your rights or our obligations pertaining to the protection of Your Personal Data (and insofar as we have a means to contact you), we will notify you of the update by adequate means based on the information we may have collected.

However, we advise you to visit the page of this Website Privacy Policy regularly to verify any updates.

WHO IS RESPONSIBLE FOR THE PROCESSING OF PERSONAL DATA ON THIS WEBSITE (THE CONTROLLER)?

Genzyme Corporation is responsible for the processing of Personal Data of individuals using this website and therefore acts as the Controller:

Genzyme Corporation
50 Binney Street,
Cambridge, Massachusetts 02142
Tel.: + 1 (617) 252-7500

REMINDER: WHAT IS PERSONAL DATA & PROCESSING?

For the purposes of this Website Privacy Policy, Personal Data is any information relating to an identified or identifiable natural person, for all data processing carried out in the framework of its business and activities.

To make things clear, it is any information that relates to an individual. Such Personal Data can take the form of:

Basic identification information such as your name or date of birth;
Information that can be attributed to you directly or indirectly – such as a post on a social media;
Information which can be associated to you or your device such as, for instance, an IP address (i.e. the network address of your machine);
Etc.

In this respect, the notion of “processing” designates any action that is undertaken on your Personal Data such as, for instance:

Collection;
Storage;
Access;
Analysis;
Deletion;
Etc.

WHAT PERSONAL DATA DOES THIS WEBSITE COLLECT?

When operating, this Website may collect the following categories of Personal Data:

Connection data: any information regarding your connection and access to this Website (e.g. type of machine and browser used, timestamp of your connection, IP address, pages visited, etc.), browsing history
Location data: information that may be provided by your machine and browser about your location if you allow such information to be shared with Sanofi

Data relating to and data which may be collected by cookies: for more information about cookies, please click here to view our cookies policy (the cookies policy can be accessed by clicking the appropriate tab found here.) In addition, this website embeds poll functionality which asks survey questions regarding health conditions. The responses to the survey questions are collected anonymously and aggregated with other responses in order to show collective results. The poll is multiple-choice with no option for free text.

FOR WHAT PURPOSES DOES THIS WEBSITE COLLECT PERSONAL DATA?

Any processing of Personal Data must be implemented for a defined purpose. In this respect, the collection and processing of Personal Data on this Website is conducted for the following purposes:

To personalize your browsing experience: when using our services; ensure that our services are presented in the way that best suits you; understand your professional and personal interests in our content, products and services or other content and adapt our content to your needs and preferences; present you products and offers tailored to you.
To improve our products and services: identify usage trends and develop new products and services; understand how you and your device interacts with our services; track and respond to safety concerns; determine the effectiveness of our promotional campaigns, conduct surveys.

ON WHAT GROUNDS DOES THIS WEBSITE PROCESS YOUR PERSONAL DATA?

For the purposes of this Website, your Personal Data is only processed on the basis of:

your prior CONSENT: where you have clearly expressed your approval of SANOFI’s processing of your Personal Data. In practice, this will generally mean that SANOFI will ask you to sign a document, or to fill-in an online “opt-in” form or to follow any relevant procedure to allow you to be fully informed and then either clearly accept or refuse the envisaged Personal Data processing. By navigating this Website and, if relevant, consenting to the processing of your Personal Data using cookies (as per our cookies policy).
a contractual relationship between you and SANOFI: in such case, the processing of your Personal Data is generally necessary to the execution or the performance of the contract; this means that if you do not wish SANOFI to process your Personal Data in that context, SANOFI may or will be obliged to refuse to enter into such contract with you or will not be able to provide the products or services covered in this contract.
the “legitimate interest” of SANOFI in the sense of applicable data protection law. In such a case, SANOFI shall consider your fundamental rights and interests in determining whether the processing is legitimate and lawful.

HOW LONG IS THE PERSONAL DATA COLLECTED ON THIS WEBSITE RETAINED?

The Personal Data collected on this Website will be retained for the following periods, depending on the categories of Personal Data processed

Connection data: Session duration
Location data: Two years

data relating to and data which may be collected by cookies: Please see the cookies policy. The cookies policy can be accessed by clicking the appropriate tab found here.

WHO HAS ACCESS TO PERSONAL DATA

SANOFI may transfer your Personal Data both internally (i.e. to other SANOFI entities) and/or externally to third party service providers for the purposes outlined above.

Where such internal or external transfer of Personal Data implies the transfer of your Personal Data to a country providing a lower level of protection to Personal Data than generally afforded in your jurisdiction, SANOFI will ensure that a sufficient level of protection is provided to your Personal Data by implementing adequate safeguards such as the European Standard Contractual Clauses, the SANOFI Binding Corporate Rules or asking for your prior explicit consent.

YOUR RIGHTS: SANOFI WILL ENSURE THAT YOU CAN EXERCISE YOUR RIGHTS PERTAINING TO YOUR PERSONAL DATA

You can exercise your rights as provided by applicable data protection laws.

To that end, SANOFI informs you that you are entitled:

to have access upon simple request to your Personal Data – in which case you may receive a copy of such data (if requested), unless such data is made directly available to you, for instance within your personal account;
to obtain a rectification of your Personal Data should your Personal Data be inaccurate, incomplete or obsolete;
to obtain the deletion of your Personal Data in the situations set forth by applicable data protection law (‘right to be forgotten’);
to withdraw your consent to the processing of Persona Data processing without affecting the lawfulness of processing, where your Personal Data has been collected and processed on the basis of your consent;
to object to the processing of your Personal Data, where your Personal Data has been collected and processed on the basis of legitimate interests of SANOFI, in which case you will need to justify your request by explaining to us your particular situation;
to request a limitation of the processing of Personal Data processing in the situations set forth by applicable data protection law;
to receive your Personal Data for transmission from SANOFI to a third-party or to have your Personal Data directly transferred by SANOFI to the third-party of your choice, where technically feasible (data portability right allowed only where the processing is based on your consent)

If you would like to exercise any of these rights, please contact us as described in the “How to Contact Us” section below and we will take necessary steps to respond as soon as possible.

You may also file a complaint before a competent data protection authority regarding the processing of your Personal Data. While we suggest that you contact us beforehand, if you wish to exercise this right, you should contact directly the competent data protection authority.

HOW TO CONTACT US

SANOFI welcomes any questions or comments you may have regarding this Website Privacy Policy or its implementation. You can send any request pertaining to SANOFI’s use of your Personal Data to our Data Protection Officer at the following email address: privacy-office-global@sanofi.com.

You are now leaving TheNextBreath.com

Sanofi Genzyme and Regeneron do not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi Genzyme and Regeneron make no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi Genzyme and Regeneron necessarily endorse such website and/or database.

CANCEL CONTINUE

You are now leaving TheNextBreath.com

CANCEL CONTINUE

COOKIE POLICY

WHAT IS A COOKIE?

A cookie is a small data file stored on your computer or mobile device at the request of your browser when you visit this Website. The cookie allows the website to “remember” your actions or preference for a certain period of time. Most browsers allow cookies by default. However, users can set their browsers to refuse or remove them, if they wish.

There are different types of cookies:

Session cookies are deleted when you close your browser.
Permanent cookies remain on your device or computer until they expire or until you actively delete them. They enable certain information about your use to be recalled when you return to the website.

A cookie can temporarily store anonymous information about the use and users of a website.

WHAT COOKIES DOES SANOFI USE ON THIS WEBSITE?

Some cookies are necessary to be able to use the website, others allow customization and optimization of the content displayed, the collection of user preferences or the monitoring of the audience of the website, website errors and the securing of its access.

On our Website, we and our service providers use permanent cookies.

SANOFI is using cookies if you have properly consented through the cookies banner. If your consent is already given, the banner will not appear again as long as the cookie expiry term has not come to an end. If you do not want our Website to install cookies on your browser, you can disable cookies on the cookie settings page or by modifying your browser settings. In this case, certain pages of the Website may not function properly.

On this Website, we use cookies to measure audience and your use of the Website and to improve it.

ESSENTIAL COOKIES

These cookies are required for this Website to work, for example allowing users to remain logged into their account. Essential cookies cannot be disabled.

COOKIE NAME	COOKIE DESCRIPTION	COOKIE EXPIRY TERM
ASP.NET_SessionID	Preserves the visitor's session state across page requests.	Session
JSESSIONID	Used in J2EE web application which is used in session tracking	Session

MARKETING/PERFORMANCE COOKIES

COOKIE NAME	COOKIE DESCRIPTION	COOKIE EXPIRY TERM
_fbp	Used by Facebook to deliver a series of advertisement products such as real time bidding from third party advertisers.	3 Months
_ga	This cookie name is associated with Google Universal Analytics - which is a significant update to Google's more commonly used analytics service. This cookie is used to distinguish unique users by assigning a randomly generated number as a client identifier. It is included in each page request in a site and used to calculate visitor, session and campaign data for the sites analytics reports.	2 years
_gat_UA	Pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.	1 minute
_gcl_au	Used by Google AdSense for experimenting with advertisement efficiency across websites using their services	Session
_gid	This cookie name is associated with Google Universal Analytics. Store and update a unique value for each page visited	24 hours
External_referer	This cookie is set by Twitter to identify and track the website visitor.	Session
fr	Used by Facebook to deliver a series of advertisement products such as real time bidding from third party advertisers.	3 Months
Guest_id	This cookie is set by Twitter to identify and track the website visitor.	Session
Personalization_id	This cookie carries out information about how the end user uses the website and any advertising that the end user may have seen before visiting the said website.	Session

WHAT IF YOU DO NOT WANT COOKIES TO BE USED ON YOUR BROWSER?

You can block the use of cookies or remove cookies that are already installed on your browser. We draw your attention to the fact that disabling cookies may prevent you from accessing certain features on our Website and other websites.

You can set your browser to accept or reject all cookies, to be notified when a cookie is issued, to check its validity, duration and content and to periodically delete cookies.

You can also type “cookies” in your browser's help section to access the setup instructions.
For information about how to manage cookies on the browser of your mobile device, you will need to consult the device manual.

For more information about cookies, including how they are installed and how you can manage and delete them, visit www.allaboutcookies.org.

References

Emmerman et al. Prospective Multicenter Study of Relapse Following Treatment for Acute Asthma Among Adults Presenting to the Emergency Department. CHEST. 1999. 115(4):919-27
Price et al. Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in five European countries. J Asthma. 2014. 51(2):127-35
Chipps et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2012 Aug;130(2):332-42
Price et al. Asthma control and management in 8,000 European patients: the Recognise Asthma and Link to Symptom and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014. 12(24):14009
Sastre et al. Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada. World Allergy Organ J. 2016. 4(9):13
Global Initiative for Asthma (GINA). Pocket Guide for Asthma Management and Prevention. 2019. Available at: https://ginasthma.org/2018-pocket-guide-for-asthma-management-and-prevention/. Last Accessed August 2019
Fletcher & Hiles. Continuing discrepancy between patient perception of asthma control and real-world symptoms: a quantitative online survey of 1,083 adults with asthma from the UK. Prim Care Respir J. 2013. 22(4): 431-438
McDonald et al. Health-related quality of life burden in severe asthma. Med J Aust. 2018. 209(S2): S28-S33

SUA ASMA ESTÁ REALMENTE BEM CONTROLADA?

REPENSE O QUE
VOCÊ SABE
SOBRE A ASMA

REPENSE O QUE
VOCÊ SENTE SOBRE A ASMA

REPENSE O QUE
VOCÊ FAZ
SOBRE A ASMA

REPENSE SUA ASMA

ENTENDENDO O CONTROLE DA ASMA

CONHECENDO O SEU TIPO DE ASMA

CONVERSANDO COM O SEU MÉDICO

PLANEJANDO O CONTROLE DA ASMA

SEGUINDO O PLANO

VOCÊ ESTÁ SE SENTINDO LIMITADO POR SEUS PÓLIPOS NASAIS?

MOVENDO O FUTURO, JUNTOS

#RepenseRespire